Cencora, Inc.

A severe stress scenario combines volume contraction at anchor customer Walgreens Boots Alliance with customer credit impairment and elevated balance sheet leverage following the American Oncology Network acquisition. Walgreens represents 25% of consolidated revenue and 38% of accounts receivable net of incentives, for which Cencora generally does not require collateral. If Walgreens accelerates retail store closures and reduces distribution share below 18%, domestic warehouse fixed costs would fail to absorb volume loss, compressing operating margins toward 1.1%. In the event of an anchor customer credit restructuring, bad-debt provisions against $3.13B in cash and $9.17B in invested capital would freeze operating cash flow conversion below $2.50B. Compounded by $14.46B in total debt and ~$1.7B in initial cash outlay for AON, pre-tax debt costs would rise above 5.97% and required cost of equity would elevate well beyond 7.61%, triggering severe valuation contraction.

Narrow

Cencora commands a Narrow economic moat rooted in irreplaceable nationwide distribution scale and efficient logistics across the United States pharmaceutical supply chain. Together with McKesson and Cardinal Health, Cencora operates as part of an entrenched wholesale triopoly that collectively distributes more than 90% of all domestic pharmaceuticals. In fiscal 2025, U.S. Healthcare Solutions generated $290.98B in revenue and $3.57B in segment operating income, demonstrating the earnings stability enabled by distributing essential therapeutics.

The primary structural source of Cencora's moat is scale advantage. Operating at thin gross margins across the wholesale drug distribution industry creates insurmountable economic barriers to prospective entrants. Replicating Cencora's capital-intensive temperature-controlled facilities, specialized handling of complex specialty drugs and GLP-1 therapies, and sophisticated regulatory tracking systems would require tens of billions in capital with no assurance of securing manufacturer volume discounts. Furthermore, long-term relationships with major anchor clients like Walgreens Boots Alliance (25% of revenue) and Evernorth Health Services (13% of revenue) provide predictable procurement volume.

Offsetting these advantages, Cencora's moat is bounded to Narrow rather than Wide due to intense customer concentration and customer bargaining leverage. With its two largest customers accounting for 38% of consolidated revenue, and Walgreens representing 38% of trade accounts receivable net of incentives, Cencora possesses limited standalone pricing flexibility. While the acquisition of American Oncology Network for $2.4B enterprise value builds out higher-margin provider network switching costs, wholesale distribution fee contracts remain subject to periodic renegotiation and payer cost-containment pressures.

Cencora, Inc. (COR) trades at 15.7x forward earnings against a peer median of 16.2x. Its EV/EBITDA of 13.8x compares with a peer median of 14.5x. The comparison uses 4 peers: Cardinal Health Inc., McKesson Corporation, Henry Schein Inc. and Boston Scientific Corporation, as of 2026-10-21 to 2026-10-22.

We recommend a Hold stance on Cencora, Inc.. Cencora's narrow moat, dominant domestic triopoly position, and $3.21B in annual free cash flow support steady long-term compounding. However, with market price ($340.43) slightly above intrinsic fair value ($328.59) (-3.48% implied return) and acute customer concentration in Walgreens Boots Alliance (25% revenue, 38% receivables), current valuation offers insufficient margin of safety to justify new capital allocation.^4,5,7

Investors currently holding Cencora should maintain positions to benefit from specialty pharmaceutical volume growth, GLP-1 distribution, and oncology MSO expansion following the American Oncology Network acquisition. Prospective buyers should await a pullback before establishing fresh exposure.